Ogenix Corporation (Ogenix), a medical technology company, has received a GSA Schedule (FSS contract), effective August 1, 2009 for its EPIFLO product line, PR LEAP reported. This product line allows doctors to treat chronic wounds using a continuous stream of oxygen on a 24/7 basis. The contract provides government organizations, particularly VA hospitals and military facilities to more easily acquire EPIFLO units for treatment of chronic and difficult to heal wounds.

GSA Schedules allow government purchases using commercial buying practices to purchase high-quality products at volume discount pricing on a direct-delivery basis. Other benefits of GSA Schedules include shorter lead-times, lower administrative costs and reduced inventories.

Ogenix is a developer, manufacturer, and marketer of small, portable oxygen generation devices used in wound care.